An in-depth review of AI-powered advancements in cancer drug discovery

IF 4.2 2区生物学 Q2 BIOCHEMISTRY & MOLECULAR BIOLOGY Biochimica et biophysica acta. Molecular basis of disease Pub Date : 2025-01-19 DOI:10.1016/j.bbadis.2025.167680

Minh Huu Nhat Le , Phat Ky Nguyen , Thi Phuong Trang Nguyen , Hien Quang Nguyen , Dao Ngoc Hien Tam , Han Hong Huynh , Phat Kim Huynh , Nguyen Quoc Khanh Le

{"title":"An in-depth review of AI-powered advancements in cancer drug discovery","authors":"Minh Huu Nhat Le , Phat Ky Nguyen , Thi Phuong Trang Nguyen , Hien Quang Nguyen , Dao Ngoc Hien Tam , Han Hong Huynh , Phat Kim Huynh , Nguyen Quoc Khanh Le","doi":"10.1016/j.bbadis.2025.167680","DOIUrl":null,"url":null,"abstract":"<div><div>The convergence of artificial intelligence (AI) and genomics is redefining cancer drug discovery by facilitating the development of personalized and effective therapies. This review examines the transformative role of AI technologies, including deep learning and advanced data analytics, in accelerating key stages of the drug discovery process: target identification, drug design, clinical trial optimization, and drug response prediction. Cutting-edge tools such as DrugnomeAI and PandaOmics have made substantial contributions to therapeutic target identification, while AI's predictive capabilities are driving personalized treatment strategies. Additionally, advancements like AlphaFold highlight AI's capacity to address intricate challenges in drug development. However, the field faces significant challenges, including the management of large-scale genomic datasets and ethical concerns surrounding AI deployment in healthcare. This review underscores the promise of data-centric AI approaches and emphasizes the necessity of continued innovation and interdisciplinary collaboration. Together, AI and genomics are charting a path toward more precise, efficient, and transformative cancer therapeutics.</div></div>","PeriodicalId":8821,"journal":{"name":"Biochimica et biophysica acta. Molecular basis of disease","volume":"1871 3","pages":"Article 167680"},"PeriodicalIF":4.2000,"publicationDate":"2025-01-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Biochimica et biophysica acta. Molecular basis of disease","FirstCategoryId":"99","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S0925443925000250","RegionNum":2,"RegionCategory":"生物学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"BIOCHEMISTRY & MOLECULAR BIOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

The convergence of artificial intelligence (AI) and genomics is redefining cancer drug discovery by facilitating the development of personalized and effective therapies. This review examines the transformative role of AI technologies, including deep learning and advanced data analytics, in accelerating key stages of the drug discovery process: target identification, drug design, clinical trial optimization, and drug response prediction. Cutting-edge tools such as DrugnomeAI and PandaOmics have made substantial contributions to therapeutic target identification, while AI's predictive capabilities are driving personalized treatment strategies. Additionally, advancements like AlphaFold highlight AI's capacity to address intricate challenges in drug development. However, the field faces significant challenges, including the management of large-scale genomic datasets and ethical concerns surrounding AI deployment in healthcare. This review underscores the promise of data-centric AI approaches and emphasizes the necessity of continued innovation and interdisciplinary collaboration. Together, AI and genomics are charting a path toward more precise, efficient, and transformative cancer therapeutics.

Abstract Image

查看原文

微信好友朋友圈 QQ好友复制链接

本刊更多论文

深入回顾人工智能在癌症药物发现方面的进展。

人工智能（AI）和基因组学的融合通过促进个性化和有效疗法的发展，正在重新定义癌症药物的发现。本综述探讨了人工智能技术的变革作用，包括深度学习和高级数据分析，在加速药物发现过程的关键阶段：目标识别、药物设计、临床试验优化和药物反应预测。DrugnomeAI和PandaOmics等尖端工具为治疗靶点识别做出了重大贡献，而人工智能的预测能力正在推动个性化治疗策略。此外，像AlphaFold这样的进步凸显了人工智能解决药物开发中复杂挑战的能力。然而，该领域面临着重大挑战，包括大规模基因组数据集的管理以及围绕人工智能在医疗保健领域部署的伦理问题。这篇综述强调了以数据为中心的人工智能方法的前景，并强调了持续创新和跨学科合作的必要性。人工智能和基因组学共同绘制了一条通往更精确、更有效和更具变革性的癌症治疗方法的道路。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文去求助

来源期刊

Biochimica et biophysica acta. Molecular basis of disease 生物-生化与分子生物学

CiteScore

12.30

自引率

0.00%

发文量

218

审稿时长

32 days

期刊介绍： BBA Molecular Basis of Disease addresses the biochemistry and molecular genetics of disease processes and models of human disease. This journal covers aspects of aging, cancer, metabolic-, neurological-, and immunological-based disease. Manuscripts focused on using animal models to elucidate biochemical and mechanistic insight in each of these conditions, are particularly encouraged. Manuscripts should emphasize the underlying mechanisms of disease pathways and provide novel contributions to the understanding and/or treatment of these disorders. Highly descriptive and method development submissions may be declined without full review. The submission of uninvited reviews to BBA - Molecular Basis of Disease is strongly discouraged, and any such uninvited review should be accompanied by a coverletter outlining the compelling reasons why the review should be considered.